Development and validation of a high-content screening assay for inhibitors of enteropathogenic E. coli adhesion

J Microbiol Methods. 2021 May:184:106201. doi: 10.1016/j.mimet.2021.106201. Epub 2021 Mar 10.

Abstract

Enteropathogenic E. coli (EPEC) causes intestinal infections leading to severe diarrhea. EPEC attaches to the host cell causing lesions to the intestinal epithelium coupled with the effacement of microvilli. In the process, actin accumulates into a pedestal-like structure under bacterial microcolonies. We designed an automated fluorescence microscopy-based screening method for discovering compounds capable of inhibiting EPEC adhesion and virulence using aurodox, a type three secretion system (T3SS) inhibitor, as a positive control. The screening assay employs an EPEC strain (2348/69) expressing a fluorescent protein and actin staining for monitoring the bacteria and their pedestals respectively, analyzing these with a custom image analysis pipeline. The assay allows for the discovery of compounds capable of preventing the formation of pathogenic actin rearrangements. These compounds may be interfering with virulence-related molecular pathways relevant for developing antivirulence leads.

Keywords: A/E lesion; Antivirulence drug discovery; Enteropathogenic E. coli; Fluorescence microscopy; High-content screening; T3SS.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Automation / methods*
  • Bacterial Adhesion / drug effects*
  • Drug Evaluation, Preclinical / methods*
  • Enteropathogenic Escherichia coli / drug effects*
  • Enteropathogenic Escherichia coli / genetics
  • Enteropathogenic Escherichia coli / pathogenicity
  • Enteropathogenic Escherichia coli / physiology*
  • Escherichia coli Infections / microbiology
  • Escherichia coli Proteins / antagonists & inhibitors
  • Escherichia coli Proteins / metabolism
  • Humans
  • Microscopy, Fluorescence / methods*
  • Type III Secretion Systems / antagonists & inhibitors
  • Type III Secretion Systems / metabolism
  • Virulence / drug effects

Substances

  • Anti-Bacterial Agents
  • Escherichia coli Proteins
  • Type III Secretion Systems